Evolva Coordinated Sale Process To End

Reinach, Switzerland, 18 August 2011 – Evolva Holding SA (SIX: EVE) announced today that one of the parties to the coordinated sale agreement that was announced by Evolva on December 13, 2010 and extended on May 17, 2011 has given notice of its intention to end its participation in the coordinated sale process.

This is expected to lead to the discontinuation of the coordinated sales process as of Friday 19 August 2011, with the remaining shares that were included in the process being returned to the parties on or after 30 August, 2011. Thereafter each party is free to trade its shares at its own discretion.

This development does not affect the unlocking of the approx. 51 million locked-up shares (c. 29.5% of Evolva’s issued capital) which will take place on 1 September 2011, as planned. This will bring the process of gradually unlocking those of Evolva’s shares that were locked at the time of the merger with Arpida in December 2009 to completion.

Neil Goldsmith, CEO of Evolva, commented: “The coordinated sale has been a very beneficial process for Evolva and for all of our shareholders. It has allowed a gradual and orderly unwinding of the lock-up that was established in December 2009. With the announcement of the CHF 30 million SEDA facility earlier this week this is a good time for Evolva to transition to a normal stock trading situation. We would like to thank our core shareholders for their support.”

– ends –

About Evolva Holding SA

Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. For more information visit www.evolva.com.

Download PDF:

• Press release in English

Contact Details

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.